Liposomes are well-established carrier systems, presenting significant advantages over other nanoparticle-based drug delivery systems. The advantages include a high load carrying capacity, low cytotoxicity, and a versatile nature in terms of possible formulations and functionalization. Mesenchymal stem cells(MSCs) have received considerable attention by the scientific community because of their potential of expansion and the ability to differentiate into various mesodermal tissues. The main objective of the present study is to evaluate the efficacy of liposomes as carriers of a functional bioactive agent, dexamethasone (Dex). In particular, we aim at validating those carriers in the induction of the osteogenic differentiation of mesenchymal stem cells (MSCs).